Sagimet Biosciences Inc. · Brief

Next report

9 days

Nov 12 · before openest.Q3 FY26

Expected move

±10.3%implied · report alone

8.6910.69

straddle ±14.0%

spot 9.69exp Nov 20ATM strike 10ATM straddle 1.60IV 91%

Nov 2 closereport share · term structure

Expected move

—≥ implied

Q2 FY26±12.4%▼−0.52%×0.04

quarterimplied−15%0+15%realized×

Q2 FY26±12.4%▼−0.52%×0.04

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 12 report · est.

Bull2 of 4

4disclosed supplier and customer ties in SEC filingsSEC filings

4tracked funds holding SGMTN-PORT · Aug 31 '26

Bear2

0.07%of State Street SPDR S&P Biotech ETF's assets, the largest tracked-fund weightN-PORT · Jun 30 '26

21managers whose positions together make up four fifths of the reported value13F · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

SGMT report session

No linked exposure.

Oct 29impliedImplied move: ±15.1% into Nov 12 earnings (Oct 29 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.